Multiple large-scale studies, including a 2025 multisite cohort across six population-based databases and a 2024 Scandinavian cohort study with 3.9 years mean follow-up, found no evidence that GLP-1 receptor agonist use is associated with increased thyroid cancer risk compared to DPP-4 inhibitor use.

Evidence (2)

GLP-1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study

Six-country multisite cohort study found no evidence of increased thyroid cancer risk with GLP-1RA use over 1.8-3.0 year follow-up.

https://pubmed.ncbi.nlm.nih.gov/39772758/

Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study

Large Scandinavian cohort found no substantial increased thyroid cancer risk over 3.9 years mean follow-up.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004669/

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/99e0dceefeaee5dcf214a4d9d974be0b19020e8f8e0b8bcd851fb36eabe50a6e"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.